Somatropin Results Timeline: What Studies Measured, and When

Somatropin is recombinant human growth hormone. Across the published literature, trials and reviews did not measure one universal "result" — the endpoint depended entirely on the population studied. Growth studies in children tracked centimetres per year. Wasting and body-composition studies tracked lean body mass. Short bowel syndrome work tracked parenteral nutrition requirements. Because the endpoints differed, so did the timepoints at which researchers looked. This page summarises what was measured and when, as reported in the cited papers. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision or treatment.

Why There Is No Single Somatropin Timeline

The verified literature spans at least four distinct clinical contexts. In treatment-naïve children with growth hormone deficiency, researchers reported annualized height velocity after 12 months of daily somatropin dosed at 0.034 mg/kg/day in a phase 3 comparison against weekly somatrogon (PMID 35405011). In adults with HIV-associated wasting, reviews of mammalian cell-derived somatropin described placebo-controlled trials that measured lean body mass and physical work output over roughly 12 weeks (PMID 16526830). In short bowel syndrome, a drug profile described somatropin given as a four-week course alongside specialised nutritional support (PMID 15200350). Comparing those timelines to one another is not meaningful; each belongs to its own question.

Timepoints Reported in the Literature

The Shortest Timepoint: Four Weeks in Short Bowel Syndrome

The shortest defined treatment window in the verified literature came from gastroenterology rather than endocrinology. A drug profile of somatropin in short bowel syndrome described its use as a four-week course given together with specialised nutritional support, with parenteral nutrition requirements as the outcome of interest (PMID 15200350). A later review of pharmacologic options for intestinal rehabilitation placed somatropin among the agents studied for patients with short bowel syndrome dependent on parenteral support (PMID 24615689). Readers looking for "how long does somatropin take to work" should note that this four-week figure is a protocol duration in one specific gastrointestinal indication — it is not a general onset estimate and was never presented as one in that profile (PMID 15200350).

Around Twelve Weeks: Body Composition Endpoints

Two reviews of mammalian cell-derived somatropin in HIV-associated wasting summarised randomised, placebo-controlled trials in which the primary measurements were lean body mass and treadmill work output assessed after roughly 12 weeks of therapy (PMID 16526830). A companion spotlight article covering the same agent described the same body-composition and functional endpoints in adults with wasting associated with HIV infection (PMID 16724867). These were disease-specific trials in adults with documented wasting; the reviews did not evaluate somatropin in healthy adults, and neither article reported cosmetic or athletic endpoints (PMID 16526830).

In adults with Prader-Willi syndrome, a review of somatropin therapy discussed body composition — fat mass and lean mass — as the outcome domain studied, alongside considerations about respiratory status and metabolic monitoring (PMID 16026111). That review described an adult population with a specific genetic syndrome rather than a general population, and the timepoints reflected study protocols rather than any expected onset of change (PMID 16026111).

Twelve Months: The Standard Pediatric Growth Endpoint

In pediatric growth hormone deficiency, the field converged on a 12-month primary endpoint. The phase 3 heiGHt trial randomised treatment-naïve children to weekly lonapegsomatropin or daily somatropin at 0.034 mg/kg/day and measured annualized height velocity at week 52, with researchers reporting that the weekly agent was non-inferior to daily somatropin on that endpoint (PMID 34272849). A separate phase 3 study compared weekly somatrogon with daily somatropin at 0.034 mg/kg/day and likewise used height velocity after 12 months of treatment as its primary comparison (PMID 35405011).

Height velocity is a rate, not a snapshot. Because it is expressed in centimetres per year, the study design required a full year of measurement before the primary result existed — which is why the twelve-month timepoint recurs across these trials (PMID 35405011). Intermediate visits occurred within these protocols, but the comparison that the investigators powered the trial to answer was the one-year measurement (PMID 34272849).

Other Pediatric Populations

A review of somatropin therapy in children with Noonan syndrome examined growth outcomes in a non-GHD short stature population, discussing both short-term growth response and the more limited evidence on adult height (PMID 15966565). In central precocious puberty, a review of current treatment options centred on GnRH analogue therapy and discussed where growth hormone had been considered as an adjunct in selected children (PMID 15339200).

Years: Extension Trials and Registry Follow-Up

The longest timeframes in the verified set came from an extension trial and a registry. Final results from the enliGHten extension reported height outcomes in children with growth hormone deficiency treated with lonapegsomatropin for up to six years, with height standard deviation score tracked across that period (PMID 40049149). A broader review of long-acting growth hormone products for pediatric growth hormone deficiency placed these weekly agents alongside daily somatropin and discussed what their trial programmes had and had not yet established (PMID 40144813).

At the population level, results from the full KIGS cohort reported effectiveness and safety outcomes for pediatric growth hormone therapy accumulated across many years of observational follow-up in multiple indications (PMID 36102184). Registry data of this kind describe what happened in routine practice over long horizons; the authors presented it as observational evidence rather than as randomised comparison (PMID 36102184).

Adverse Events in Somatropin Studies: What Studies Report

Safety reporting followed the same timepoint structure as efficacy reporting. The full KIGS cohort analysis was framed explicitly around both safety and efficacy of pediatric growth hormone therapy over long-term follow-up, making it the largest safety dataset in this verified set (PMID 36102184). In the phase 3 somatrogon comparison, safety was assessed over the same 12-month period as the growth endpoint in children receiving either weekly somatrogon or daily somatropin (PMID 35405011), and the heiGHt trial likewise reported safety alongside its 52-week efficacy analysis (PMID 34272849).

In adult indications, the reviews addressed tolerability within their specific populations: the Prader-Willi syndrome review discussed monitoring considerations relevant to that syndrome during somatropin therapy (PMID 16026111), and the HIV-associated wasting reviews addressed the tolerability profile observed in the controlled trials they summarised (PMID 16526830). The review of long-acting growth hormone products also discussed outstanding questions about long-term safety for the weekly formulations (PMID 40144813). Anyone interpreting adverse-event data should read the primary publications rather than any summary, including this one.

What the Verified Literature Does Not Cover

Several common questions fall outside the scope of the papers cited here, and it is more useful to say so plainly than to extrapolate:

• Healthy adults. The adult studies in this set involved HIV-associated wasting (PMID 16724867), Prader-Willi syndrome (PMID 16026111) and short bowel syndrome (PMID 15200350). None enrolled healthy adults, and none reported anti-ageing, performance or physique endpoints.
• Week-by-week onset. No paper in this set defined a week at which an effect "appears." The pediatric trials were designed around a twelve-month height-velocity measurement (PMID 34272849).
• Individual prediction. Registry and trial data describe group-level outcomes; the KIGS analysis reported pooled results across a large treated population rather than individual trajectories (PMID 36102184).
• Head-to-head across indications. A four-week gastrointestinal protocol (PMID 24615689) and a six-year pediatric growth extension (PMID 40049149) answer unrelated questions and cannot be averaged into one timeline.

How to Read a Results Timeline

1. Identify the population. Children with growth hormone deficiency (PMID 35405011) and adults with wasting (PMID 16526830) are not interchangeable groups.
2. Identify the endpoint. Height velocity, lean body mass and parenteral nutrition requirement are measured in different units over different windows (PMID 15200350).
3. Check the design. Randomised comparisons (PMID 34272849) carry different weight than observational registry data (PMID 36102184).
4. Note what remains open. Reviews of newer long-acting formulations flagged unresolved long-term questions (PMID 40144813).

Somatropin is a prescription medicine in the jurisdictions where the cited trials were conducted, and the studies above were run under medical supervision with monitoring built into the protocols (PMID 36102184). This page summarises published research only and does not recommend, endorse or describe any personal use.

References

• Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial (The Journal of Clinical Endocrinology and Metabolism, 2021)
• Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results (Hormone Research in Paediatrics, 2026)
• Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency (Journal of the Endocrine Society, 2025)
• Somatropin therapy in adults with Prader-Willi syndrome (Treatments in Endocrinology, 2004)
• Mammalian cell-derived somatropin: a review of its use in the management of HIV-associated wasting (Drugs, 2006)
• Spotlight on mammalian cell-derived somatropin in HIV-associated wasting (BioDrugs, 2006)
• Somatropin (Zorbtive): in short bowel syndrome (Drugs, 2004)
• Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome (JPEN, 2014)
• The role of somatropin therapy in children with Noonan syndrome (Treatments in Endocrinology, 2003)
• Central precocious puberty: current treatment options (Paediatric Drugs, 2004)